<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124499">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064673</url>
  </required_header>
  <id_info>
    <org_study_id>042013-080</org_study_id>
    <nct_id>NCT02064673</nct_id>
  </id_info>
  <brief_title>Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy</brief_title>
  <official_title>Randomized Trial of Adjuvant Curcumin After Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study to determine if the adjuvant use of Curcumin improves
      recurrence-free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study to determine if the adjuvant use of Curcumin improves
      recurrence-free survival in patients after radical prostatectomy compared to placebo
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Serum prostate specific antigen</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recurrence free survival defined as a total serum prostate specific antigen of &lt;0.2ng/ml.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Curcumin 500 mg orally twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo orally twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin or placebo 500mg by mouth twice a day for 6 months</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>Bio-Curcumin(BCM-95CG)</other_name>
    <other_name>Tumeric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo orally twice a day</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>sugar pill</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  radical prostatectomy for adenocarcinoma of prostate

          -  pathologically confirmed T1-T3 disease

          -  no sign of lymph node or metastatic disease

          -  Eastern Cooperative Oncology Group(ECOG) status 0-2

          -  adequate renal and liver function

          -  no plan to receive adjuvant hormone or radiation therapy

          -  life expectancy of 3 years

        Exclusion Criteria:

          -  must not have exceeded 3 months from time of surgery to enrollment into study

          -  T3b or T4 or node positive disease

          -  hormone therapy before surgery

          -  history of gallbladder problems or gallstones, or biliary obstruction

          -  radiation therapy as primary treatment after surgery

          -  antiplatelet or anticoagulant agents

          -  history of gastric or duodenal ulcers or hyperacidity syndromes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yair Lotan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison Beaver, RN, BSN</last_name>
    <phone>214-645-8787</phone>
    <email>Allison.Beaver@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Beaver, RN, BSN</last_name>
      <phone>214-645-8787</phone>
      <email>Allison.Beaver@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Yair Lotan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>radical prostatectomy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
